HIV, antiretroviral therapy, and hypertensive disorders in pregnancy: A systematic review and meta-analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 1, 2015, Pages 91-98

  Browne, Joyce L ^a   Schrier, Verena J M M ^a   Grobbee, Diederick E ^a   Peters, Sanne A E ^a,b   Klipstein Grobusch, Kerstin ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

eclampsia; HAART; HIV; pre eclampsia; pregnancy induced hypertension

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; COCHRANE LIBRARY; CONFERENCE PAPER; DISEASE ASSOCIATION; ECLAMPSIA; EMBASE; FEMALE; GENETIC HETEROGENEITY; HELLP SYNDROME; HIGH RISK PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MATERNAL HYPERTENSION; MEDLINE; META ANALYSIS; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; COMPLICATION; HIV INFECTIONS; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS, INFECTIOUS;

ANTI-RETROVIRAL AGENTS; ECLAMPSIA; FEMALE; HELLP SYNDROME; HIV INFECTIONS; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT;

EID: 84939803216     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000686     Document Type: Conference Paper

References (67)

1. UN Joint Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic: 2010. UNAIDS, Geneva, Switzerland; 2010. Available at: http://www.refworld.org/docid/4cfca9c62.html. Accessed May 20, 2014
2. Calvert C, Ronsmans C. HIV and the risk of direct obstetric complications: a systematic review and meta-Analysis. PLoS One. 2013; 8: e74848
3. Aboud S, Msamanga G, Read JS, et al. Effect of prenatal and perinatal antibiotics on maternal health in Malawi, Tanzania, and Zambia. Int J Gynaecol Obstet. 2009; 107: 202-207
4. Kourtis AP, Bansil P, McPheeters M, et al. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003. AIDS. 2006; 20: 1823-1831
5. Onah HE, Obi SN, Agbata TA, et al. Pregnancy outcome in HIV-positive women in Enugu, Nigeria. J Obstet Gynaecol. 2007; 27: 271-274
6. Chanrachakul BU, Herabutya Y, Panburana P. Active management of labor: is it suitable for a developing country? Int J Gynaecol Obstet. 2001; 72: 229-234
7. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-Analysis. Br J Obstet Gynaecol. 1998; 105: 836-848
8. Olagbuji BN, Ezeanochie MC, Ande AB, et al. Obstetric and perinatal outcome in HIV positive women receiving HAART in urban Nigeria. Arch Gynecol Obstet. 2010; 281: 991-994
9. DreyfussML, Msamanga GI, Spiegelman D, et al. Determinants of low birth weight among HIV-infected pregnant. Am J Clin Nutr. 2001; 74: 814-826
10. Goldstein PJ, Smit R, Stevens M, et al. Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants. Infect Dis Obstet Gynecol. 2000; 98: 94-98
11. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. AIDS. 1998; 12: 1992-1994
12. Nkhoma ET, Kalilani-Phiri L, Mwapasa V, et al. Effect of HIV infection and Plasmodium falciparum parasitemia on pregnancy outcomes in Malawi. Am J Trop Med Hyg. 2012; 87: 29-34
13. Boer K, Nellen J, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG. 2007; 114: 148-155
14. Parekh N, Ribaudo H, Souda S, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-Age infants among HIV-exposed and HIV-unexposed infants in Botswana. Int J Gynaecol Obstet. 2011; 115: 20-25
15. Zaba B, Calvert C, Marston M, et al. Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA). Lancet. 2013; 381: 1763-1771
16. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014; 2: e323-e333
17. Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006; 368: 1189-1200
18. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993; 341: 1447-1451
19. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-1594
20. Hall D, Gebhardt S, Theron G, et al. Pre-eclampsia and gestational hypertension are less common in HIV infected women. Pregnancy Hypertens An Int J Womens Cardiovasc Health. 2014; 4: 91-96
21. Munoz-Suano A, Hamilton AB, Betz AG. Gimme shelter: the immune system during pregnancy. Immunol Rev. 2011; 241: 20-38
22. Steegers EAP, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010; 376: 631-644
23. Govender N, Naicker T, Moodley J. Maternal imbalance between proangiogenic and anti-Angiogenic factors in HIV-infected women with preeclampsia. Cardiovasc J Afr. 2013; 24: 174-179
24. Fourie C, van Rooyen J, Pieters M, et al. Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Afr. 2011; 22: 134-140
25. Short CE, Douglas M, Smith JH, et al. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-To-child transmission. HIV Med. 2014; 15: 233-238
26. Connor EM, Sperling RS, Gelber R. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331: 1173-1180
27. Duong T, Ades AE, Gibb DM, et al. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ. 1999; 319: 1227-1229. Available at: http://www.pubmedcentral.nih.gov/articlerenderfcgi?artid=28270&tool=pmcentrez&rendertype=abstract. Accessed May 23, 2014
28. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010; 362: 2282-2294
29. Siegfried N, van der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-To-child transmission of HIV infection. Cochrane Database Syst Rev. 2011; 7: 1361-1367
30. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007; 44: 493-499
31. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-Associated endothelial dysfunction. J Investig Med. 2008; 56: 752-769
32. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100
33. Schrier V, Browne J, Klipstein-Grobusch K. The relationship between HIV, antiretroviral therapy and hypertensive disorders in pregnancy: a systematic review. PROSPERO 2014. Available at: http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42014009529. Accessed June 3, 2015
34. IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp
35. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration Version 5.1.0. Cochrane Collaboration Group, London, UK; 2011. Available at: http://www. cochrane.org/handbook. Accessed May 23, 2014
36. StataCorp. Stata Statistical Software: Release 11. College Station, Texas: StataCorp LP; 2009
37. Bansil P, Jamieson DJ, Posner SF, et al. Hospitalizations of pregnant HIVinfected women in the United States in the era of highly active antiretroviral therapy (HAART). J Womens Health (Larchmt). 2007; 16: 159-162
38. Bodkin C, Klopper H, Langley G A comparison of HIV positive and negative pregnant women at a public sector hospital in South Africa. J Clin Nurs. 2006; 15: 735-741
39. Chamiso D. Pregnancy outcome in HIV-1 positive women in Gandhi Memorial hospital Addis Ababa, Ethiopia. East Afr Med J. 1996; 73: 805-809
40. Da Costa TP, Leal MC, Mota JC, et al. Comparison of pregnancy characteristics and outcomes between HIV-infected and HIV-noninfected women in Brazil. AIDS Care. 2013; 25: 686-690
41. Figuero-Damián R. Pregnancy outcome in women infected with the human immunodeficiency virus [in Spanish]. Salud Publica Mex. 1999; 41: 362-367
42. Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against preeclampsia-eclampsia? Obstet Gynecol. 2004; 104: 238-242
43. De Groot MR, Corporaal LJ, Cronjé HS, et al. HIV infection in critically ill obstetrical patients. Int J Gynaecol Obstet. 2003; 81: 9-16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12676387
44. Haeri S, Shauer M, Dale M, et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol. 2009; 201: 315.e1-315.e5
45. Lionel J, Aleyamma T, Varghese L, et al. HIV and obstetric complications and fetal outcomes in Vellore, India. Trop Doct. 2008; 38: 144-146
46. Mmiro F, Ndugwa C, Guay L, et al. Effect of human immunodeficiency virus-1 infection on the outcome of pregnancy in Ugandan women. Pediatr AIDS HIV Infect Fetus Adolesc. 1993; 4: 67-73. Available at: http://www.popline.org/node/333786. Accessed May 21, 2014
47. Patil S, Bhosale R, Sambarey P, et al. Impact of maternal human immunodeficiency virus infection on pregnancy and birth outcomes in Pune, India. AIDS Care. 2011; 23: 1562-1569
48. Román-Poueriet J, Fernandez AD, Beck-Sagué CM, et al. HIV infection and prevention of mother-To-child transmission in childbearing women: La Romana, Dominican Republic, 2002-2006. Rev Panam Salud Publica. 2009; 26: 315-323. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20107679
49. Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can. 2012; 34: 136-141. Available at: http://www.ncbi.nlm.nih. gov/pubmed/22340062
50. Geary FH, Lindsay MK, Graves WL, et al. Human immunodeficiency virus infection is not a risk factor for adverse perinatal outcomes. J Maternal Fetal Med. 1995; 34: 29-34
51. Mattar R, Amed AM, Lindsey PC, et al. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol. 2004; 117: 240-241
52. Minkoff H, Henderson C, Mendez H, et al. Pregnancy outcomes among mothers infected with human inmmunodeficiency virus and uninfected control subjects. Am J Obstet Gynecol. 1990; 163: 1598-1604
53. Ngene NC, Moodley J, Songca P, et al. Maternal and fetal outcomes of HIV-infected and non-infected pregnant women admitted to two intensive care units in Pietermaritzburg, South Africa. S Afr Med J. 2013; 103: 543-548
54. Singh YA, Usham R, Devi SR, et al. Foeto-maternal outcome in HIV infected women and measures to prevent parent-To-child transmission of HIV. J Med Soc. 2009; 23: 116-120
55. Suy A, Martínez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS. 2006; 20: 59-66. Available at: http://www.ncbi. nlm.nih.gov/pubmed/16327320
56. Waweru J, Mugenda O, Kuria E. Anemia in the context of pregnancy and HIV/AIDS: a case of Pumwani Maternity Hospital in Nairobi, Kenya. Afr J Food Agric Nutr Dev. 2009; 9: 748-763
57. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 2002; 360: 1152-1154. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12387967
58. Bera E. Maternal outcomes following introduction of antiretroviral therapy in the public sector: a prospective study at a tertiary hospital in the Eastern Cape. SAJOG. 2009; 15: 26-33
59. Roberts JM, August PA, Bakris G, et al. Hypertension in pregnancy. Am Coll Obstet Gynaecol. 2013; 122: 1122-1131
60. Firnhaber C, Smeaton L, Saukila N, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010; 14: e1088-e1092
61. Kalumba VMS, Moodley J, Naidoo TD. Is the prevalence of preeclampsia affected by HIV/AIDS? A retrospective case-control study. Cardiovasc J Afr. 2013; 24: 24-27
62. Powis KM, McElrath TF, Hughes MD, et al. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana. J Acquir Immune Defic Syndr. 2013; 62: 517-524
63. Calvert C, Ronsmans C. The contribution of HIV to pregnancy-related mortality: a systematic review and meta-Analysis. AIDS. 2013; 27: 1631-1639
64. Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-Analysis of individual patient data. Lancet. 2007; 369: 1791-1798
65. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2. doi: 10.1002/14651858.CD004659.pub2
66. Hofmeyr GJ, Lawrie TA, Atallah AN, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010; 8: CD001059. doi: 10.1002/14651858.CD001059.pub3
67. National Committee for the Confidential Enquiries into Maternal Deaths. Saving Mothers 2008-2010: Fifth Report on Confidential Enquiries into Maternal Deaths in South Africa. Pretoria, South Africa; 2012